Search

Displaying results 801 - 810 of 4860 in total
  1. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    [A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  2. Drug

    Trichophyton mentagrophytes

    go.drugbank.com/drugs/DB10446
    Approved

    Trichophyton mentagrophytes is a fungus which can provoke allergic reactions. Trichophyton mentagrophytes extract is used in allergenic testing.

    Mixtures: Mold Mix C, Mold Mix C
  3. Drug

    Amaranthus retroflexus pollen

    go.drugbank.com/drugs/DB10381
    Approved

    Amaranthus retroflexus pollen is the pollen of the Amaranthus retroflexus plant. Amaranthus retroflexus pollen is mainly used in allergenic testing.

    Mixtures: 3 Weed Mix, 3 Weed Mix
  4. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

  5. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC).

  6. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.

  7. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]

  8. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113] … The peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated fat from which the major component is [DB04224].

  9. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

  10. Drug

    Rumex acetosella pollen

    go.drugbank.com/drugs/DB10359
    Approved

    Rumex acetosella pollen is the pollen of the Rumex acetosella plant. Rumex acetosella pollen is mainly used in allergenic testing.

    Mixtures: Dock-Sorrel Mix, Dock-Sorrel Mix